[HTML][HTML] Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
E Blass, PA Ott - Nature reviews Clinical oncology, 2021 - nature.com
Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …
cancers with the development and regulatory approval of various immune-checkpoint …
[引用][C] Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
E Blass, PA Ott - Nature Reviews Clinical Oncology, 2021 - cir.nii.ac.jp
Advances in the development of personalized neoantigen-based therapeutic cancer
vaccines | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
vaccines | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.
E Blass, PA Ott - Nature reviews. Clinical Oncology, 2021 - europepmc.org
Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …
cancers with the development and regulatory approval of various immune-checkpoint …
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
E Blass, PA Ott - Nature reviews. Clinical oncology, 2021 - pubmed.ncbi.nlm.nih.gov
Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …
cancers with the development and regulatory approval of various immune-checkpoint …
[HTML][HTML] Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
E Blass, PA Ott - Nature Reviews. Clinical Oncology, 2021 - ncbi.nlm.nih.gov
Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …
cancers with the development and regulatory approval of various immune-checkpoint …